ndas 21-389/772 etoricoxib robert b. shibuya, m.d. medical officer division of anesthesia,...
TRANSCRIPT
![Page 1: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/1.jpg)
NDAs 21-389/772Etoricoxib
Robert B. Shibuya, M.D.Medical Officer
Division of Anesthesia, Analgesia, and Rheumatology Products
![Page 2: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/2.jpg)
2
Efficacy
• 30 mg dose– Four Phase 3 studies (2 vs. placebo and
ibuprofen, 2 vs. placebo and celecoxib)– All positive
• 60 mg dose– Two Phase 3 studies (both vs. placebo and
naproxen)– Both positive
![Page 3: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/3.jpg)
3
Efficacy-dose response at 6 weeks
![Page 4: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/4.jpg)
4
Efficacy-dose response over 14 weeks
![Page 5: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/5.jpg)
5
Cross-study comparison of etoricoxib efficacy at 30 and 60 mg
![Page 6: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/6.jpg)
6
Efficacy-representative plot, Study 077-WOMAC pain
![Page 7: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/7.jpg)
Etoricoxib Safety Program
![Page 8: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/8.jpg)
8
MEDAL Program
• MEDAL/EDGE/EDGE II Studies• R, DB, AC, PG trials of the “large simple” design
– MEDAL enrolled OA/RA– EDGE enrolled OA– EDGE II enrolled RA
• Active control = diclofenac 150 mg/day• Etoricoxib dosed at 60 or 90 mg/day
![Page 9: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/9.jpg)
9
MEDAL Program
• Endpoints– MEDAL = CV– EDGE/EDGE II = GI
• All used identical adjudication procedures• N = 34,701, mean f/u = 20,19, and 9 months • EDGE/EDGE II collected data on less severe AEs• ASA/GPAs permitted
![Page 10: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/10.jpg)
10
Non-MEDAL database
• Comprised of 18 conventional Phase 2/3 studies – Populations: OA, RA, AS, CLBP– N = ~4,500 – Duration: 4 to 52 weeks– Controls: Placebo, Ibuprofen, Diclofenac,
Naproxen, Celecoxib– Doses of etoricoxib: 5-120– Collected data for all AEs– ASA/GPAs sometimes permitted, sometimes
not
![Page 11: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/11.jpg)
Cardiovascular Safety
![Page 12: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/12.jpg)
12
CV Safety-APTC EndpointPooled MEDAL Program
Analysis population
Treatment Rate
(per 100PYR) 95% CI
Relative Risk (95%
CI)
ITT Etoricoxib 0.83 (0.75,0.93)
1.02 (0.87,1.18)
ITT Diclofenac 0.82 (0.73,0.91)
Per Protocol
Etoricoxib 0.84 (0.73,0.95)
0.96 (0.79,1.16)
Per Protocol
Diclofenac 0.87 (0.76,1.00)
![Page 13: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/13.jpg)
13
CV Safety – MEDAL – APTC(by dose, OA only), ITT population
Etoricoxib dose mg
Etoricoxib
Rate per 100 PYR
(95% CI)
Matched Diclofenac Rate per 100 PYR
(95% CI)
Relative Risk
(95% CI)
60 0.76 (0.64,0.91)
0.71
(0.59,0.85)
1.07 (0.83,1.37)
90 0.91
(0.74,1.11)
0.70
(0.56,0.88)
1.30 (0.96,1.75)
![Page 14: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/14.jpg)
14
Relative vs. Attributable Risk
• Relative Risk = Quotient of the rate in Group A and the rate in Group B (estimated by Cox Proportional Hazards Model)
• Attributable Risk = Arithmetic difference in rates between Groups A & B
![Page 15: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/15.jpg)
15
Attributable Risk-MEDAL Data-APTC/OA only
Treatment N n/PYR Rate (per 100 PYR) (95% CI)
Relative Risk
Δ in risk (in 100 person-year)
(95% CI)
Etoricoxib 12,533 231/28175 0.82 (0.72,0.93)
1.15 (0.95,1.40)
0.11 (-0.035,0.25)
Diclofenac 12,380 198/27856 0.71 (0.62,0.82)
Etoricoxib
90 mg
5,764 99/10894 0.91 (0.74,1.11)
1.30 (0.96,1.75)
0.20 (-0.034,0.44)
Matched Diclofenac
5,680 76/10789 0.70 (0.56,0.88)
Etoricoxib
60 mg
6,769 132/17280 0.76 (0.64,0.91)
1.07 (0.84,1.37)
0.049 (-0.13,0.23)
Matched Diclofenac
6,700 122/17067 0.71 (0.59,0.85)
![Page 16: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/16.jpg)
16
Mortality/Morbidity based on Attributable Risk Subgroup Analysis
• Based on the point estimate, if etoricoxib were prescribed to 1,000,000 patients:– 490 excess patients would experience an APTC event
on etoricoxib 60 mg than if they had taken diclofenac.– High estimate (upper limit of the 95% CI) - 2,300
excess events could occur compared to diclofenac treatment
– Low estimate (lower limit of the 95% CI) – 1,300 fewer events could occur compared to diclofenac treatment
![Page 17: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/17.jpg)
17
CV safety-non-MEDALTreatment N Cases/PYR* Rate (95% CI)‡ Relative Risk**
(95% CI)
Etoricoxib 3940 7/810 0.86 (0.35,1.78) 1.95 (0.37,19.19)
Placebo 2337 2/450 0.44 (0.05,1.60)
Etoricoxib 2147 11/1817 0.61 (0.30,1.08) 0.80 (0.25,2.59)
Non-Naproxen NSAIDs
1470 4/649 0.62 (0.17,1.58)
Etoricoxib 1960 27/2481 1.09 (0.72,1.58) 2.72 (1.18,6.27)
Naproxen 1497 7/1728 0.41 (0.16,0.83)
* Patient-years at risk
‡ Per 100 PYR
** Relative risk using Cox model stratified by therapeutic block where the number of cases is at least 11, otherwise relative risk is ratio of rates
![Page 18: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/18.jpg)
Gastrointestinal Issues
![Page 19: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/19.jpg)
19
GI Event Adjudication
• Categorize– Confirmed vs. unconfirmed– Complicated vs. not complicated
![Page 20: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/20.jpg)
20
UGI Safety-MEDAL-Confirmed Cases only
Etoricoxib (N = 17,412-26,388 PYR)
Diclofenac (N = 17,289 – 25,378 PYR)
Definition of event
# of events
Rate 95% CI # of events
Rate 95% CI
Complicated only
78 0.30 0.23, 0.37 82 0.32 0.26, 0.40
Combined 176 0.67 0.57,0.77 246 0.97 0.85,1.10
![Page 21: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/21.jpg)
21
UGI Safety-MEDAL-Confirmed Cases only
Etoricoxib (N = 17,412 – 26,388 PYR)
Diclofenac (N = 17,289 – 25, 378 PYR)
Specific Event # events complicated
only
# events combined
# events complicated
only
# events combined
Ulceration 38 175 32 249
Perforation 5 5 11 11
Obstruction 2 2 2 2
Hemorrhage 70 78 71 76
![Page 22: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/22.jpg)
22
LGI Safety-MEDAL-Confirmed Cases only
Etoricoxib (N = 17,412-26,382 PYR)
Diclofenac (N = 17,289 – 25,386 PYR)
Definition of event # of events
Rate 95% CI # of events
Rate 95% CI
Complicated only 77 0.29 0.23, 0.36 87 0.34 0.27, 0.42
Combined 84 0.32 0.25,0.39 96 0.38 0.31,0.46
![Page 23: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/23.jpg)
23
UGI safety-non-MEDAL, confirmed PUBs only-
Treatment n/N (%) Person-years
Rate* 95% CI for Rate
Relative Risk**
95% CI for RR
Complicated only
Etoricoxib 19/4107 (0.46)
4300 0.44 (0.27,0.69) 0.57 (0.31,1.07)
Nonselective NSAIDs
23/2967 (0.78)
2378 0.97 (0.61,1.45)
Combined
Etoricoxib 40/4107 (0.97)
4294 0.93 (0.67,1.27) 0.47 (0.31,0.72)
Nonselective NSAIDs
55/2967 (1.85)
2373 2.32 (1.75,3.02)
*Number of events per 100 person-years
**Relative risk was calculated using a Cox model stratified by protocol and with terms for treatment and the 3 risk factors. The p-value for testing the proportionality assumption is 0.546.
![Page 24: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/24.jpg)
24
UGI safety benefit largely driven by comparison to naproxen
![Page 25: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/25.jpg)
25
GI tolerability-MEDAL
![Page 26: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/26.jpg)
Renovascular Safety
![Page 27: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/27.jpg)
27Neaton et al. Arch Inter Med 1992
![Page 28: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/28.jpg)
28Prospective Studies Collaboration Lancet 2002 (Stroke mortality, left panel, IHD mortality, right panel)
![Page 29: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/29.jpg)
29
Renovascular Safety Program
• Effects on Blood Pressure– Discontinuations for HTN-related AEs– HTN-related AEs– Mean difference in baseline for systolic and diastolic
BP– Proportions meeting prespecified increases in systolic
and diastolic BP
• Congestive Heart Failure• Edema• Pertinent laboratory abnormalities
![Page 30: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/30.jpg)
30
RV safety - MEDAL - HTN
![Page 31: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/31.jpg)
31
RV safety – MEDAL - Edema
![Page 32: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/32.jpg)
32
RV safety – MEDAL - CHF
![Page 33: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/33.jpg)
33
RV safety - MEDAL – Lab Events
![Page 34: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/34.jpg)
34
RV safety-Non-MEDAL (placebo-controlled)
Cohort N HTN-related AE (%) Edema-related AE (%)
Placebo 1035 2.9 1.8
E < 30 231 1.3 3.0
E 30 1014 3.7 3.6
E 60 558 4.8 2.9
E 90 220 5.0 1.8
E 120 288 6.6 3.1
Naproxen 494 4.0 2.8
Ibuprofen 756 6.3 4.6
Celecoxib 200 488 1.2 3.3
Celecoxib 400 107 1.9 2.8
![Page 35: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/35.jpg)
35
RV Safety-Non-MEDAL (6 & 12-mo AC)
6-mo AC 12-mo AC
Cohort N Edema-related AE
(%)
HTN-related AE
(%)
Edema-related AE
(%)
HTN-related AE
(%)
E 30 474/55 5.3 5.7 3.6 7.3
E 60 508 5.3 11.8
E 90 112 7.1 9.8
C 200 488 4.9 2.3
N 1000 439 6.4 8.4
![Page 36: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/36.jpg)
36
Hepatic Safety
![Page 37: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/37.jpg)
37
Hepatic safety-MEDAL
![Page 38: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/38.jpg)
38
Summary of Efficacy Findings
• Etoricoxib is effective at doses of 30 and 60 mg/day.
• One Phase 2 clinical trial shows some evidence of dose response between 5 and 60 mg with wide confidence intervals after 6 weeks of treatment. The differences between doses diminish as the study progressed beyond 6 weeks.
• Cross-study comparisons do not show evidence of added benefit for the 60 mg dose.
![Page 39: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/39.jpg)
39
Summary of Safety Findings
• Cardiovascular thromboembolic events– As assessed by relative risk, the pooled
MEDAL data show comparable CV risk versus diclofenac.
– However, given the 95% CI, the attributable risk for etoricoxib compared to diclofenac could be as high as 2,300 excess events per million patient-years.
– The non-MEDAL database suggests that etoricoxib is inferior to naproxen.
![Page 40: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/40.jpg)
40
Summary of Safety Findings
• Renovascular Safety– Etoricoxib 90 mg causes more hypertension, edema,
and congestive heart failure than diclofenac.
– Etoricoxib 60 mg causes more hypertension and slightly more edema and CHF than diclofenac.
– Compared to other NSAIDs (celecoxib, ibuprofen, and naproxen), 30 and 60 mg of etoricoxib appears mixed for renovascular safety (conclusions less robust due to relatively low exposures compared to diclofenac).
![Page 41: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/41.jpg)
41
Summary of Safety Findings
• Gastrointestinal events– For medically significant upper GI events,
etoricoxib approximates diclofenac and appears to be superior to naproxen.
– For nonserious GI-related symptoms, etoricoxib is superior to diclofenac and naproxen.
![Page 42: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/42.jpg)
42
Spacer
![Page 43: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/43.jpg)
43
Efficacy-representative plot, Study 071-WOMAC pain
![Page 44: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/44.jpg)
44
Efficacy-representative plot, Study 019-WOMAC Pain
![Page 45: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/45.jpg)
45
Attributable Risk-MEDAL Data-APTC/Pooled data and RA only
Treatment Patient
Population
n/PYR Rate (per 100 PYR) (95% CI)
Relative Risk
Δ in risk (in 100 person-year)
(95% CI)
Etoricoxib MEDAL
Program
332/39894 0.83 (0.73,0.91)
1.02 (0.87,1.18)
0.01 (-0.11,0.14)
Diclofenac 325/39623 0.82 (0.73,0.91)
Etoricoxib
60/90 mg
MEDAL Study
265/31469 0.84 (0.74,0.95)
1.08 (0.91,1.28)
0.06 (-0.08,0.20)
Matched Diclofenac
245/31243 0.78 (0.69,0.89)
Etoricoxib
90 mg
RA Patients
101/11717 0.86 (0.70,1.05)
0.80 (0.62,1.04)
-0.22 (-0.05,0.003)
Matched Diclofenac
127/11767 1.08 (0.90,1.28)
![Page 46: NDAs 21-389/772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products](https://reader036.vdocuments.mx/reader036/viewer/2022062519/5697c0011a28abf838cc262e/html5/thumbnails/46.jpg)
46
Mean change in SBP from baseline